The Super Cell Blocker, ONC-127, drug candidate is a major breakthrough in inhibiting a process known as glycolysis which “starves the tumor” by blocking its ability to provide energy for the cell to live. The founding scientists have designed a drug that passes through the Blood Brain Barrier (BBB) which is the brain’s security mechanism that stops most other drugs from reaching the brain in order to target the brain tumor and is also selectively taken up by brain tumor cells. This technology is also applicable to other cancers that have a high sugar uptake such as breast and pancreatic cancers.

This technology is covered under Oncolin’s recent exclusive option to license from The University of Texas M.D. Anderson Cancer Center which is one of the world’s leading cancer treatment facilities.

About Oncolin Therapeutics, Inc.

Headquartered in Houston, Texas, Oncolin Therapeutics, Inc. is a publicly traded biopharmaceutical company that engages in the discovery, development and commercialization of novel selective anticancer therapies. Additional information about Oncolin can be found on the web at www.oncolinthera.com.

Safe Harbor Statement

This press release contains statements that may constitute forward-looking statements, including the company’s ability to successfully acquire and develop technologies that are and may be acquired. These statements are based on current expectations and assumptions and involve a number of uncertainties and risks that could cause actual results to differ materially from those currently expected. For additional information about Oncolin’s future business and financial results, refer to Oncolin’s Quarterly Report on Form 10-QSB for the quarter ended December 31, 2007 and Annual Report on Form 10-KSB for the year ended March 31, 2007. Oncolin Therapeutics undertakes no obligation to update any forward-looking statement that may be made from time to time by or on behalf of the company, whether as a result of new information, future events or otherwise.

Contact:

Oncolin Therapeutics, Inc., Houston
J. Leonard Ivins, 832-426-7909
Investors@oncolinthera.com

Source: Oncolin Therapeutics, Inc.

StockGuru.com is owned and operated by Pentony Enterprises LLC, 10604 Robincreek Lane, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Pentony Enterprises LLC has been compensated $12,000 from a non-controlling third party for profile coverage. Previously we have been compensated $25,400 from a non-controlling third party.Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

Disclosure: Pentony Enterprises LLC was compensated two million restricted shares from the company and 700,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all free trading shares of this and any company featured. Anyone considering any company we feature should consider this. In accordance with our policy to sell all free trading shares, we have sold all free trading shares and hold the two million restricted shares.

Share This Article:

Yesterday’s Close: $0.062

Today’s Intraday High: $0.075

View the StockGuru Profile for VMCS:
http://www.stockguru.com/profiles/vmcs/

Disclosure: Pentony Enterprises LLC has been compensated $30,000 by a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

Disclosure: Pentony Enterprises LLC was compensated $15,000 from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

Onconlin has recently announced that is has obtained an exclusive option agreement with the Pharmaceutical Research Institute of Warsaw, Poland which provides the company the right to license the use of Genistein analogs for cancer treatment.

The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw Poland and involves compounds that appear to be novel antimicrotubule agents.

“We are happy to have obtained this exclusive agreement on what may be another unique antimicrotubule class of compounds. We will work closely with both the Pharmaceutical Research Institute of Warsaw Poland and the University of Texas MD Anderson Cancer Center to further evaluate the compounds’ anticancer activity in order to advance a lead compound into clinical development,” said Dr. Donald Picker, President and COO of the company.

The microtubule is perhaps the single best cancer target identified to date and continues to be recognized as a strategic target against which to direct new development efforts.

Antimicrobubule drugs, agents that interfere with cell division, has resulted in several billion dollars in yearly sales.

Oncolin Therapeutics anti-microtubule agent can potentially have a large sales volume, given the wide use of this type of drug.

Oncolin Therapeutics’ antimicrotuble drug will acts upon solid tumors, such as breast, prostate, lung, and ovarian.

Sources: Biotech Businessweek, April 3, 2008, April 14, 2008; National Cancer Institute

StockGuru.com is owned and operated by Pentony Enterprises LLC, 10604 Robincreek Lane, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Pentony Enterprises LLC has been compensated $12,000 from a non-controlling third party for profile coverage. Previously we have been compensated $25,400 from a non-controlling third party.Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

On April 30th, RHGP Closed at $0.825

On May 7th, it Closed at $0.90

Yesterday RHGP Closed at $1.01 and Today’s High So Far is $1.20!

View the StockGuru Profile for RHGP:
http://stockguru.com/profiles/rhgp/

Disclosure: Pentony Enterprises LLC expects to be compensated as much at $12,300 for profile coverage from StockPromoters.com. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

All Fuels and Energy intends to have produce ethanol at a low cost by seeking to build and/or acquire large-scale facilities with design elements that incorporate technology improvements and continue to build and/or acquire facilities in locations with access to multiple rail services.

To date, AFSE has obtained $2.3 million in private equity funding; purchased 150 acres on which to build its proposed ethanol production facility in Manchester, Iowa; signed a five-plant engineering and design agreement; engaged Natural Resources Group to handle water-related environmental matters relating to the proposed Manchester ethanol production facility; engaged Yaggy-Colby to handle air-related environmental matters relating to the proposed Manchester ethanol production facility; and investigated and become involved in the potential acquisition of one or more existing ethanol production facilities

* In March 2007, our subsidiary, ALL Energy Company, through its subsidiary, ALL Energy Manchester, LLC, acquired approximately 150 acres of real property located near Manchester, Iowa. The facility will be capable of producing 100 million gallons of ethanol per year—meeting 20% of All Fuel and Energy’s ethanol production goals.

* Air quality and water quality construction permits, related to the Manchester facility have already been obtained.
* A feasibility study, conducted by BBI, confirms adequate supplies and infrastructure.

The feasibility study confirmed that there are ample corn supplies in close proximity to the Manchester facility to satisfy our feedstock needs, that there are adequate supplies of energy available at reasonable cost with which to operate the Manchester facility and that the surrounding transportation infrastructure is capable of handling the anticipated truck and rail traffic associated with the Manchester facility.

* Proposed purchase of another facility in Stanley, WI to produce another 30 million gallons of ethanol per year, allowing All Fuel and Energy to meet 26% of its production goals.
* All Fuels and Energy is currently negotiating the acquisition of one or more additional existing ethanol production facilities.

Source: http://www.allfuelsandenergy.com, May 12, 2008

StockGuru.com is owned and operated by Pentony Enterprises LLC, 10604 Robincreek Lane, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated $12000 from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

The “Superlattice Structure” will allow electric vehicles to be driven over 200 miles compared to the current 120 to 140 mile range. In addition, electric vehicles will operate at a wide voltage range of 4.3V to 2V. The pure material was produced in-house and has been synthesized at an industrial scale.

Advantages of the superlattice structure:

* Low or zero exothermic reaction
* High capacity (170 Ah/kg or more)
* Non-toxic and disposable
* Low cost

The high density “Superlattice Structure” is suitable not only for large batteries in electric vehicles but can also be used in the field of “Uninterrupted Power Supply (UPS)”.

Source: Automotive Industries, March 2008, Hybridtechnologies.com, May 2008.

StockGuru.com is owned and operated by Pentony Enterprises LLC, 10604 Robincreek Lane, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC and its affiliates have been compensated $55,000 from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

Striker Oil & Gas, Inc. (OTCBB: SOIS) - Monday’s shares rose 20.24% to $0.60. 51,510 shares were traded. Striker Oil & Gas announced May 6ththat it expects fiscal 2008 revenue to increase to $5,000,000 versus $3,000,000 for fiscal 2007. This would represent a 66% increase and would be attributed to continued development and remediation of its current prospects. In addition, Striker had previously announced it was attempting a recompletion on its Cayuga prospect and has since determined that this new zone was found to be uneconomical to produce. Striker and its partners will continue to evaluate the best way to proceed on this prospect which will also include a review of all formations and a possible farm-out. “We are very happy with the expected growth for 2008 that is attributed to our current prospects,” said Kevan Casey, Chief Executive Officer of Striker. “In addition, we are continuing to search for new acquisitions and developments that will further increase our cash flow, reserves and ultimately shareholder value.”

Striker Oil & Gas, Inc. is an upstream U.S. oil and gas company engaged in the search for and sale of oil and gas reserves through both exploratory drilling and the acquisition of producing properties. Striker’s objective is to cost-efficiently develop these properties and market the oil and gas production at the wellhead. Striker is strategically focused along the Texas Gulf Coast, East Texas and South Louisiana in areas of developed infrastructure and established markets.

Oncolin Therapeutics, Inc. (OTCBB: OCOL)

Oncolin Therapeutics, Inc. (OTCBB: OCOL) - Monday’s shares increased 10% to $0.33. The volume was 19,960. Oncolin Therapeutics, Inc. announced May 5th that Dr Randall K. Johnson agreed to join the Scientific Advisory Board of the company joining a growing number of illustrious oncologists and cancer drug developers. Dr Johnson began his career as section Head of the Experimental Chemotherapy at the National Cancer Institute. Most of his accomplishments occurred over more than twenty years at Glaxo SmithKline where he held various senior positions in oncology culminating in Oncology Group Director. Among the many accomplishments during his tenure was the development of Topotecan which continues to be a major drug used in cancer therapy today. For the past five years Dr Johnson has consulted for numerous drug and biotech companies and is a member of many Scientific Advisory Boards and clinical advisory Boards for oncology based companies.

Oncolin Therapeutics, Inc. is a biopharmaceutical company focused on developing drugs which interfere with the key mechanisms of cancer tumor development. The company engages in the discovery, development and commercialization of novel selective anticancer therapies. The company has a lead drug for brain cancer in preclinical development licensed from the MD Anderson Cancer Center. Oncolin is focused on the development of this drug to clinical development with an IND scheduled to be filed in approximately 18 months [ Investigational New Drug (application to the FDA) ]. The company also has a robust pipeline of oncology research programs that are mainly funded by Federal grants.

ALL Fuels & Energy Company (OTCBB: AFSE)

ALL Fuels & Energy Company (OTCBB: AFSE) - Monday’s shares decreased 8.11% to $0.34. 19,864 was the volume. ALL Fuels & Energy (AFSE) announced May 5th that its new subsidiary, AFSE Enzyme, signed a letter of intent with a research and development institution that would host the company’s “super” enzyme research and development. With the letter of intent process completed, AFSE Enzyme will begin the process of negotiating licensing and marketing agreements, which is expected to be completed within 90 days. “The selection of this research institution has been running on a parallel track with our ongoing testing of our first super enzyme’s capacity for boosting production of corn and cellulosic ethanol,” said Dean Sukowatey, AFSE President. “We remain excited about commercializing this super enzyme that could result in a possible production costs savings of up to 50%.”

ALL Fuels & Energy Company is a development-stage ethanol company organized to operate as an ethanol producer, focusing primarily on the production and sale of ethanol and its co-products. To date, AFSE has: obtained $2.3 million in private equity funding; purchased 150 acres on which to build its proposed ethanol production facility in Manchester, Iowa; signed a five-plant engineering and design agreement; engaged Natural Resources Group to handle water-related environmental matters relating to the proposed Manchester ethanol production facility; engaged Yaggy-Colby to handle air-related environmental matters relating to the proposed Manchester ethanol production facility; and investigated and become involved in the potential acquisition of one or more existing ethanol production facilities.

Essential Innovations Technology Corp. (OTCBB: ESIV)

Essential Innovations Technology Corp. (OTCBB: ESIV) - Monday’s shares stayed even at $0.115. 25,500 shares were traded. Essential Innovations Technology announced May 5th that Mr. Stephen Clevett, President & CEO of Optimira Energy Canada, Ltd. (”Optimira”), officially joined the ESIV Board of Directors. “With the inclusion of Mr. Stephen Clevett to the ESIV Board of Directors, we continue to make great strides towards our goal of attracting to the Company external skills and guidance from individuals with powerful credentials and proven industry prowess in their particular or chosen fields of expertise. Mr. Clevett has extensive background in the financing, structuring and operation requisites that apply to traditional conventional ESCO projects. He now brings this skill set to ESIV and gives our Company the benefit of an inherent advantage when we enter into negotiations and ultimately look to facilitate Geoexchange ESCO projects. Mr. Clevett’s direct ESCO experience combined with his business and finance background, makes him a wonderful complement to the last Board addition we had made in latter 2006, of Mr. Salvador Diaz-Verson, the former President/CIO of AFLAC and founder of Miramar Securities a registered broker/dealer in Atlanta, Georgia. Mr. Diaz-Verson had initially brought to the ESIV Board of Directors a history of truly top-level world-class finance and capital market knowledge, and with the formal addition of Mr. Clevett now complete we are nearing our final objective of having a totally independent, superlative Board membership that can help our management team to enhance and bring further credibility to our current and future business. Mr. Clevett joining our team is representative of our successful pursuit of specific endeavors that will help to enhance our Board and ultimately that will help us to flourish and to achieve our long-term growth plan for the Company,” commented Jason McDiarmid, President/CEO of ESIV.

Essential Innovations Technology Corp. provides cutting-edge Geoexchange solutions for residential, commercial and industrial applications as both a Geoexchange energy service company and as a manufacturer of proprietary geothermal heat pump technology. Essential Innovations manufactures and distributes its proprietary cutting edge GeoExchange System, the “EI Elemental Series”, in Vancouver, Canada. The EI Elemental family of products are high efficiency, eco-friendly comfort systems providing heating, cooling, dehumidification as well as domestic hot water production for residential, commercial and industrial applications.

Columbia River Resources Inc. (OTC: CRVR)

Columbia River Resources Inc. (OTC: CRVR) - Monday’s shares closed down 6.25% to $0.075. The volume was 128,390. Traxxec Ltd, the U.K. subsidiary of Columbia River Resources Inc. , reported April 21st negotiations to supply Glaxo SmithKline and Catalent through its new clinical trials sales division. As reported last week, the company has negotiated a policy with Rexam plc that allows it to sell directly in to the pharmaceutical clinical trial arena and to pharmaceutical contract and clinical research organisations.Catalent and Glaxo SmithKline represent two of the biggest names in the contract and pharma arena, ideal customers for the new division. In addition, Traxxec is in talks with a French-based global leader in the beauty Industry. All three companies are interested in evaluating the effectiveness of RFID in their supply chain. Such early positive results underline the importance of the new sales channels in addition to the 15-year licensing agreement currently in place with Rexam.

Columbia River Resources Inc., through its wholly owned subsidiary Traxxec Ltd, is a specialist in providing packaging solutions, in particular in relation to auto-id and Radio Frequency Identification (RFID), where it holds intellectual property and considerable practical experience and knowledge. The company’s small, focused management team has considerable expertise in providing packaging solutions and developing innovative products in a variety of industries, including pharmaceuticals, where the founders have more than 20 years experience. Strong relationships have been developed in both the global pharmaceutical industry and RFID component sectors over a period of many years. Manufacturing and Service Industries worldwide are on the cusp of a RFID transformation. Retailers, manufacturers, aerospace, defence, pharmaceutical and healthcare companies have found competitive advantage by intelligently moving the technology forward in to the business strategy playing field.

StockGuru.com is owned and operated by Pentony Enterprises LLC, 10604 Robincreek Lane, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. SOIS Disclosure: Pentony Enterprises LLC has been compensated $12,000 from a non-controlling third party for profile coverage. OCOL Disclosure: Pentony Enterprises LLC has been compensated $12,000 from a non-controlling third party for profile coverage. Previously we have been compensated $25,400 from a non-controlling third party. AFSE Disclosure: Pentony Enterprises LLC has been compensated $12,000 from a non-controlling third party for profile coverage. ESIV Disclosure: Pentony Enterprises LLC has been compensated 1.375 million free trading shares from a non-controlling third party for profile coverage. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. Pentony Enterprises currently holds one million three hundred and twenty thousand shares. CRVR Disclosure: Pentony Enterprises LLC has been compensated 500,000 shares from a non-controlling third party for profile coverage. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Share This Article:

Recompleted wells:

In Louisiana, Striker Oil and gas has recompleted its LeJeune well, to a new formation uphole from the existing depleted formation. As of April 11, 2008, the Lejeune Well No. 1 is producing approximately 140 gross barrels of oil per day.

The South Creole prospect was drilled to a depth of approximately 11,300 feet to test the Planulina A sand. During May 2007, the well began producing and as of April 11, 2008, is producing approximately 3,000 gross Mcf of gas per day and 44 gross barrels of condensate per day.

Awaiting Completion:

Drilling operations for the second Rodessa well, Catfish Creek #2 in East Texas, began in February 2008. Based upon electric logs, production casing has been run in the well and it is currently waiting on completion.

Striker Oil and Gas, Inc., along with its partners, has mineral rights to a depth of 10,600 feet, and the option to participate in wells below 10,600 feet where the hydrocarbon rich Cotton Valley and Bossier formations are located.

North Cayuga prospect in East Texas:

The Easter Seals Well No. 1-R has been drilled to a depth of approximately 9,000 feet and the well is currently being completed in the Rodessa Bacon Lime sand. The Rodessa, Pettit, Travis Peak, Georgetown, Cotton Valley and Bossier sands are also productive zones for which this geographic area is known.

This prospect, comprised of approximately 450 gross acres, has the potential for eight wells.

Awaiting Development:

In Louisiana’s Welsh Field, Striker Oil and Gas immediately repaired repair one saltwater disposal well and two shut-in wells which were not producing due to mechanical problems. Striker Oil and Gas is working to increase its saltwater disposal capacity which the Company believes will increase its production to approximately 70 gross barrels of oil per day.

Striker Oil and Gas intends to expend its capital resources to develop these projects and seek out additional opportunities for drilling of conventional reserves and acquire oil and gas producing reserves onshore within the continental United States.

Source: http://www.strikeroil.com, May 11, 2008, Form 10KSB, For the fiscal year ended December 31, 2007

StockGuru.com is owned and operated by Pentony Enterprises LLC, 10604 Robincreek Lane, Frisco, Texas 75035. Telephone: (469) 252-3030. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC has been compensated $12,000 from a non-controlling third party for profile coverage. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.